Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection
Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results. We aimed to investigate the effect of a commercially available DOAC absorbent on residual...
Saved in:
Published in | Thrombosis research Vol. 204; pp. 32 - 39 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Ltd
01.08.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results.
We aimed to investigate the effect of a commercially available DOAC absorbent on residual drug concentrations, and on integrated procedures for LA-detection.
Blood from patients treated for atrial fibrillation with either dabigatran (n = 39), rivaroxaban (n = 55), apixaban (n = 47) or edoxaban (n = 47) were collected at peak and trough, and centralized for testing with two LA integrated procedures [i.e., the silica clotting time (SCT) and dilute Russel viper venom (dRVVT)] before and after DOAC absorbent exposure.
The commercially available DOAC absorbent investigated in this study proved effective in reducing the concentrations of all the investigated DOAC, although small residual drug was detected after absorption, especially in patients on edoxaban.
Results mimicking LA were observed in patients on DOAC before absorbent exposure, especially for rivaroxaban when testing was performed with dRVVT (88% rate at peak and 20% at trough) and much less with SCT (12% at peak and 8% at trough). The correspondent rate of results mimicking LA in patients on rivaroxaban after exposure was reduced [dRVVT (peak 8%, trough 4%); SCT (peak and trough 8%)], but not abolished.
Overall, in vitro DOAC absorbance by active charcoal compounds is a useful laboratory tool for LA-detection in patients on DOAC. Caution should however be exerted when used in daily practice.
•DOAC may lead to results mimicking lupus anticoagulant (LA).•Active charcoal is effective in reducing DOAC concentrations from plasma.•Results mimicking LA are common in rivaroxaban plasma tested with Russel venom test.•After rivaroxaban removal, results mimicking LA are reduced but not abolished. |
---|---|
AbstractList | BACKGROUNDLupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results. AIMSWe aimed to investigate the effect of a commercially available DOAC absorbent on residual drug concentrations, and on integrated procedures for LA-detection. METHODSBlood from patients treated for atrial fibrillation with either dabigatran (n = 39), rivaroxaban (n = 55), apixaban (n = 47) or edoxaban (n = 47) were collected at peak and trough, and centralized for testing with two LA integrated procedures [i.e., the silica clotting time (SCT) and dilute Russel viper venom (dRVVT)] before and after DOAC absorbent exposure. RESULTSThe commercially available DOAC absorbent investigated in this study proved effective in reducing the concentrations of all the investigated DOAC, although small residual drug was detected after absorption, especially in patients on edoxaban. Results mimicking LA were observed in patients on DOAC before absorbent exposure, especially for rivaroxaban when testing was performed with dRVVT (88% rate at peak and 20% at trough) and much less with SCT (12% at peak and 8% at trough). The correspondent rate of results mimicking LA in patients on rivaroxaban after exposure was reduced [dRVVT (peak 8%, trough 4%); SCT (peak and trough 8%)], but not abolished. CONCLUSIONSOverall, in vitro DOAC absorbance by active charcoal compounds is a useful laboratory tool for LA-detection in patients on DOAC. Caution should however be exerted when used in daily practice. Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral anticoagulants (DOAC) that may lead to false-positive results. We aimed to investigate the effect of a commercially available DOAC absorbent on residual drug concentrations, and on integrated procedures for LA-detection. Blood from patients treated for atrial fibrillation with either dabigatran (n = 39), rivaroxaban (n = 55), apixaban (n = 47) or edoxaban (n = 47) were collected at peak and trough, and centralized for testing with two LA integrated procedures [i.e., the silica clotting time (SCT) and dilute Russel viper venom (dRVVT)] before and after DOAC absorbent exposure. The commercially available DOAC absorbent investigated in this study proved effective in reducing the concentrations of all the investigated DOAC, although small residual drug was detected after absorption, especially in patients on edoxaban. Results mimicking LA were observed in patients on DOAC before absorbent exposure, especially for rivaroxaban when testing was performed with dRVVT (88% rate at peak and 20% at trough) and much less with SCT (12% at peak and 8% at trough). The correspondent rate of results mimicking LA in patients on rivaroxaban after exposure was reduced [dRVVT (peak 8%, trough 4%); SCT (peak and trough 8%)], but not abolished. Overall, in vitro DOAC absorbance by active charcoal compounds is a useful laboratory tool for LA-detection in patients on DOAC. Caution should however be exerted when used in daily practice. •DOAC may lead to results mimicking lupus anticoagulant (LA).•Active charcoal is effective in reducing DOAC concentrations from plasma.•Results mimicking LA are common in rivaroxaban plasma tested with Russel venom test.•After rivaroxaban removal, results mimicking LA are reduced but not abolished. |
Author | Scalambrino, Erica Novembrino, Cristina Testa, Sophie Clerici, Marigrazia Peyvandi, Flora Boscolo-Anzoletti, Massimo Tripodi, Armando Chantarangkul, Veena Paoletti, Oriana |
Author_xml | – sequence: 1 givenname: Armando surname: Tripodi fullname: Tripodi, Armando email: armando.tripodi@unimi.it organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 2 givenname: Erica surname: Scalambrino fullname: Scalambrino, Erica organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 3 givenname: Veena surname: Chantarangkul fullname: Chantarangkul, Veena organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 4 givenname: Oriana surname: Paoletti fullname: Paoletti, Oriana organization: Ospedale Maggiore Cremona, Italy – sequence: 5 givenname: Marigrazia surname: Clerici fullname: Clerici, Marigrazia organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 6 givenname: Cristina surname: Novembrino fullname: Novembrino, Cristina organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 7 givenname: Massimo surname: Boscolo-Anzoletti fullname: Boscolo-Anzoletti, Massimo organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 8 givenname: Flora surname: Peyvandi fullname: Peyvandi, Flora organization: IRCCS Ca' Granda Ospedale Maggiore Foundation, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy – sequence: 9 givenname: Sophie surname: Testa fullname: Testa, Sophie organization: Ospedale Maggiore Cremona, Italy |
BookMark | eNqFkEtP5DAQhC0EEsPjLyAf95LQdjxxfAPNLg8JiQt3y3Ha4FESB9thxb9fo1nOnLqlrmpVfWfkeA4zEnLFoGbA2ut9nd9imCKmmgNnNbQ1ADsiG9ZJVXEh-THZAAhVNZ3oTslZSvsikExtN2R5nBZjMw2OGmrDNGG03ozjJzUfxo-mH5H-fr7dUdOnEHuci3Sm-W-gfs74Gk3GgS4xWBzWkoC6EOm4LmuiZs7eBvO6jmWjA2a02Yf5gpw4Mya8_D_Pycvdn5fdQ_X0fP-4u32qbCO2udpKGJQQzEAnlHKqc6J1veESXCtV17iuF421PaDkPZgWpCy3RioY2l7x5pz8Orwt2d5XTFlPPlkcSxgMa9J8K1jDmWCqSNuD1MaQUkSnl-gnEz81A_1FWO_1N2H9RVhDqwvAYrw5GLH0-PAYdbIe54LCx1JWD8H_9OIfcH6LOQ |
CitedBy_id | crossref_primary_10_1097_MBC_0000000000001214 crossref_primary_10_3390_jcm12206654 crossref_primary_10_3390_biomedicines9070844 crossref_primary_10_3390_diagnostics12102520 crossref_primary_10_1111_ijlh_13861 crossref_primary_10_1093_rheumatology_kead623 crossref_primary_10_3390_jcm13041042 crossref_primary_10_1055_s_0042_1749590 crossref_primary_10_3390_jcm11082164 crossref_primary_10_3390_biomedicines11061760 crossref_primary_10_37349_ei_2023_00104 |
Cites_doi | 10.1111/j.1538-7836.2006.01753.x 10.1111/ijlh.12807 10.1111/jth.14894 10.7326/M19-0291 10.3324/haematol.2017.185132 10.1111/jth.14488 10.1182/blood-2018-04-848333 10.1182/blood-2017-09-805689 10.1515/cclm-2018-0967 10.1016/j.thromres.2019.05.013 10.1016/j.thromres.2018.08.014 10.1111/jth.14935 10.1515/cclm-2018-1197 10.1111/j.1538-7836.2009.03555.x 10.1182/blood-2011-03-340232 10.1111/jth.14846 10.1111/bjh.16091 10.1097/FTD.0000000000000355 10.1111/ijlh.12950 10.1016/j.thromres.2018.01.047 10.1055/s-0037-1613259 |
ContentType | Journal Article |
Copyright | 2021 |
Copyright_xml | – notice: 2021 |
DBID | AAYXX CITATION 7X8 |
DOI | 10.1016/j.thromres.2021.06.001 |
DatabaseName | CrossRef MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-2472 |
EndPage | 39 |
ExternalDocumentID | 10_1016_j_thromres_2021_06_001 S0049384821003583 |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 0SF 123 1B1 1P~ 1RT 1~. 1~5 29Q 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABJNI ABLJU ABLVK ABMAC ABMZM ABOCM ABXDB ABYKQ ACDAQ ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEB HMK HMO HVGLF HZ~ IHE J1W J5H K-O KOM L7B LCYCR M29 M41 MO0 N9A NCXOZ O-L O9- OAUVE OC~ OO- OZT P-8 P-9 PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K WUQ X7M Z5R ZA5 ZGI ~G- AAXKI AAYXX ADVLN AFJKZ AKRWK CITATION 7X8 |
ID | FETCH-LOGICAL-c345t-570d9441a08499f98f46fba270f67983f8b43ccb0e72b0a60772703790d6b923 |
IEDL.DBID | AIKHN |
ISSN | 0049-3848 |
IngestDate | Fri Aug 16 21:07:38 EDT 2024 Thu Sep 26 15:37:47 EDT 2024 Fri Feb 23 02:45:09 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Direct oral anticoagulants Silica clotting time Dilute Russel viper venom |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c345t-570d9441a08499f98f46fba270f67983f8b43ccb0e72b0a60772703790d6b923 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PQID | 2541321419 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2541321419 crossref_primary_10_1016_j_thromres_2021_06_001 elsevier_sciencedirect_doi_10_1016_j_thromres_2021_06_001 |
PublicationCentury | 2000 |
PublicationDate | August 2021 2021-08-00 20210801 |
PublicationDateYYYYMMDD | 2021-08-01 |
PublicationDate_xml | – month: 08 year: 2021 text: August 2021 |
PublicationDecade | 2020 |
PublicationTitle | Thrombosis research |
PublicationYear | 2021 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Favaloro, Gilmore, Arunachalam, Mohammed, Baker (bb0035) 2019; 180 Exner, Ahuja, Ellwood (bb0055) 2019; 57 Exner, Michalopoulos, Pearce, Xavier, Ahuja (bb0030) 2018; 163 Ordi-Ros, Sáez-Comet, Pérez-Conesa, Vidal, Riera-Mestre, Castro-Salomó, Cuquet-Pedragosa, Ortiz-Santamaria, Mauri-Plana, Solé, Cortés-Hernández (bb0090) 2019 Miyakis, Lockshin, Atsumi, Branch, Brey, Cervera, Derksen, de Groot, Koike, Meroni, Reber, Shoenfeld, Tincani, Vlachoyiannopoulos, Krilis (bb0005) 2006; 4 Pengo, Tripodi, Reber, Rand, Ortel, Galli, De Groot, Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis (bb0025) 2009; 7 Pengo, Ruffatti, Legnani, Testa, Fierro, Marongiu, De Micheli, Gresele, Tonello, Ghirarduzzi, Bison, Denas, Banzato, Padayattil Jose, Iliceto (bb0010) 2011; 118 Boehr, Haen (bb0080) 2017; 39 De Kesel, Devreese (bb0075) 2020; 18 Tripodi, Chantarangkul, Clerici, Mannucci (bb0110) 2002; 88 Kopatz, Brinkman, Meijers (bb0050) 2018; 170 Martinelli, Abbattista, Bucciarelli, Tripodi, Artoni, Gianniello, Novembrino, Peyvandi (bb0095) 2018; 103 Tripodi, Cohen, Devreese (bb0020) 2020; 18 Pengo, Denas, Zoppellaro, Jose, Hoxha, Ruffatti, Andreoli, Tincani, Cenci, Prisco, Fierro, Gresele, Cafolla, De Micheli, Ghirarduzzi, Tosetto, Falanga, Martinelli, Testa, Barcellona, Gerosa, Banzato (bb0085) 2018; 132 Zuily, Cohen, Isenberg, Woller, Crowther, Dufrost, Wahl, Doré, Cuker, Carrier, Pengo, Devreese (bb0105) 2020; 18 Jacquemin, Toelen, Feyen, Schoeters, Van Horenbeeck, Vanlinthout, Debasse, Vanassche, Peerlinck, Verhamme (bb0040) 2018; 40 bb0100 Frans, Meeus, Bailleul (bb0045) 2019; 17 Kearon, Parpia, Spencer, Baglin, Stevens, Bauer (bb0015) 2018; 131 Ząbczyk, Kopytek, Natorska, Undas (bb0060) 2019 Cox-Morton, MacDonald, Thomas (bb0070) 2019 Platton, Hunt (bb0065) 2019; 41 De Kesel (10.1016/j.thromres.2021.06.001_bb0075) 2020; 18 Pengo (10.1016/j.thromres.2021.06.001_bb0025) 2009; 7 Platton (10.1016/j.thromres.2021.06.001_bb0065) 2019; 41 Favaloro (10.1016/j.thromres.2021.06.001_bb0035) 2019; 180 Exner (10.1016/j.thromres.2021.06.001_bb0030) 2018; 163 Ząbczyk (10.1016/j.thromres.2021.06.001_bb0060) 2019 Zuily (10.1016/j.thromres.2021.06.001_bb0105) 2020; 18 Tripodi (10.1016/j.thromres.2021.06.001_bb0110) 2002; 88 Martinelli (10.1016/j.thromres.2021.06.001_bb0095) 2018; 103 Tripodi (10.1016/j.thromres.2021.06.001_bb0020) 2020; 18 Cox-Morton (10.1016/j.thromres.2021.06.001_bb0070) 2019 Pengo (10.1016/j.thromres.2021.06.001_bb0085) 2018; 132 Kopatz (10.1016/j.thromres.2021.06.001_bb0050) 2018; 170 Exner (10.1016/j.thromres.2021.06.001_bb0055) 2019; 57 Jacquemin (10.1016/j.thromres.2021.06.001_bb0040) 2018; 40 Kearon (10.1016/j.thromres.2021.06.001_bb0015) 2018; 131 Boehr (10.1016/j.thromres.2021.06.001_bb0080) 2017; 39 Ordi-Ros (10.1016/j.thromres.2021.06.001_bb0090) 2019 Pengo (10.1016/j.thromres.2021.06.001_bb0010) 2011; 118 Miyakis (10.1016/j.thromres.2021.06.001_bb0005) 2006; 4 Frans (10.1016/j.thromres.2021.06.001_bb0045) 2019; 17 |
References_xml | – volume: 17 start-page: 1354 year: 2019 end-page: 1362 ident: bb0045 article-title: Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon publication-title: J. Thromb. Haemost. contributor: fullname: Bailleul – volume: 131 start-page: 2151 year: 2018 end-page: 2160 ident: bb0015 article-title: Julian JA. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism publication-title: Blood contributor: fullname: Bauer – volume: 41 start-page: 227 year: 2019 end-page: 233 ident: bb0065 article-title: Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban publication-title: Int. J. Lab. Hematol. contributor: fullname: Hunt – year: 2019 ident: bb0090 article-title: Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial publication-title: Ann. Intern. Med. contributor: fullname: Cortés-Hernández – volume: 180 start-page: 10 year: 2019 end-page: 19 ident: bb0035 article-title: Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa publication-title: Thromb. Res. contributor: fullname: Baker – volume: 18 start-page: 1569 year: 2020 end-page: 1575 ident: bb0020 article-title: Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis publication-title: J. Thromb. Haemost. contributor: fullname: Devreese – volume: 40 start-page: 442 year: 2018 end-page: 447 ident: bb0040 article-title: The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays publication-title: Int. J. Lab. Hematol. contributor: fullname: Verhamme – volume: 132 start-page: 1365 year: 2018 end-page: 1371 ident: bb0085 article-title: Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome publication-title: Blood contributor: fullname: Banzato – volume: 118 start-page: 4714 year: 2011 end-page: 4718 ident: bb0010 article-title: Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study publication-title: Blood contributor: fullname: Iliceto – volume: 18 start-page: 2003 year: 2020 end-page: 2017 ident: bb0075 article-title: Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing—review of the literature and evaluation on spiked and patient samples publication-title: J. Thromb. Haemost. contributor: fullname: Devreese – volume: 7 start-page: 1737 year: 2009 end-page: 1740 ident: bb0025 article-title: Update of the guidelines for lupus anticoagulant detection publication-title: J. Thromb. Haemost. contributor: fullname: Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis – volume: 170 start-page: 97 year: 2018 end-page: 101 ident: bb0050 article-title: Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay publication-title: Thromb. Res. contributor: fullname: Meijers – volume: 18 start-page: 2126 year: 2020 end-page: 2137 ident: bb0105 article-title: Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis publication-title: J. Thromb. Haemost. contributor: fullname: Devreese – volume: 57 start-page: 690 year: 2019 end-page: 696 ident: bb0055 article-title: Effect of an activated charcoal product (DOAC StopTM) intended for extracting DOACs on various other APTT-prolonging anticoagulants publication-title: Clin. Chem. Lab. Med. contributor: fullname: Ellwood – ident: bb0100 article-title: PRAC recommendations on signals. Adopted at the 8–11 April 2019 PRAC meeting. EMA Pharmacovigilance Risk Assessment Committee (PRAC) – volume: 103 start-page: e315 year: 2018 end-page: e317 ident: bb0095 article-title: Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban publication-title: Haematologica contributor: fullname: Peyvandi – volume: 4 start-page: 295 year: 2006 end-page: 306 ident: bb0005 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J. Thromb. Haemost. contributor: fullname: Krilis – volume: 88 start-page: 583 year: 2002 end-page: 586 ident: bb0110 article-title: Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA publication-title: Thromb. Haemost. contributor: fullname: Mannucci – volume: 39 start-page: 66 year: 2017 end-page: 76 ident: bb0080 article-title: Development of an UHPLC-UV-method for quantification of direct Oral anticoagulants: apixaban, rivaroxaban, dabigatran, and its prodrug dabigatran etexilate in human serum publication-title: Ther. Drug Monit. contributor: fullname: Haen – year: 2019 ident: bb0060 article-title: The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants publication-title: Clin. Chem. Lab. Med. contributor: fullname: Undas – year: 2019 ident: bb0070 article-title: A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove publication-title: Br. J. Haematol. contributor: fullname: Thomas – volume: 163 start-page: 117 year: 2018 end-page: 122 ident: bb0030 article-title: Simple method for removing DOACs from plasma samples publication-title: Thromb. Res. contributor: fullname: Ahuja – volume: 4 start-page: 295 year: 2006 ident: 10.1016/j.thromres.2021.06.001_bb0005 article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2006.01753.x contributor: fullname: Miyakis – volume: 40 start-page: 442 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0040 article-title: The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays publication-title: Int. J. Lab. Hematol. doi: 10.1111/ijlh.12807 contributor: fullname: Jacquemin – volume: 18 start-page: 2003 year: 2020 ident: 10.1016/j.thromres.2021.06.001_bb0075 article-title: Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing—review of the literature and evaluation on spiked and patient samples publication-title: J. Thromb. Haemost. doi: 10.1111/jth.14894 contributor: fullname: De Kesel – year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0090 article-title: Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial publication-title: Ann. Intern. Med. doi: 10.7326/M19-0291 contributor: fullname: Ordi-Ros – volume: 103 start-page: e315 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0095 article-title: Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban publication-title: Haematologica doi: 10.3324/haematol.2017.185132 contributor: fullname: Martinelli – volume: 17 start-page: 1354 year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0045 article-title: Resolving DOAC interference on aPTT, PT, and lupus anticoagulant testing by the use of activated carbon publication-title: J. Thromb. Haemost. doi: 10.1111/jth.14488 contributor: fullname: Frans – volume: 132 start-page: 1365 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0085 article-title: Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome publication-title: Blood doi: 10.1182/blood-2018-04-848333 contributor: fullname: Pengo – volume: 131 start-page: 2151 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0015 article-title: Julian JA. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism publication-title: Blood doi: 10.1182/blood-2017-09-805689 contributor: fullname: Kearon – volume: 57 start-page: 690 year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0055 article-title: Effect of an activated charcoal product (DOAC StopTM) intended for extracting DOACs on various other APTT-prolonging anticoagulants publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2018-0967 contributor: fullname: Exner – volume: 180 start-page: 10 year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0035 article-title: Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): a comparative study using DOAC Stop and andexanet alfa publication-title: Thromb. Res. doi: 10.1016/j.thromres.2019.05.013 contributor: fullname: Favaloro – volume: 170 start-page: 97 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0050 article-title: Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay publication-title: Thromb. Res. doi: 10.1016/j.thromres.2018.08.014 contributor: fullname: Kopatz – volume: 18 start-page: 2126 year: 2020 ident: 10.1016/j.thromres.2021.06.001_bb0105 article-title: Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis publication-title: J. Thromb. Haemost. doi: 10.1111/jth.14935 contributor: fullname: Zuily – year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0060 article-title: The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2018-1197 contributor: fullname: Ząbczyk – volume: 7 start-page: 1737 year: 2009 ident: 10.1016/j.thromres.2021.06.001_bb0025 article-title: Update of the guidelines for lupus anticoagulant detection publication-title: J. Thromb. Haemost. doi: 10.1111/j.1538-7836.2009.03555.x contributor: fullname: Pengo – volume: 118 start-page: 4714 year: 2011 ident: 10.1016/j.thromres.2021.06.001_bb0010 article-title: Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study publication-title: Blood doi: 10.1182/blood-2011-03-340232 contributor: fullname: Pengo – volume: 18 start-page: 1569 year: 2020 ident: 10.1016/j.thromres.2021.06.001_bb0020 article-title: Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis publication-title: J. Thromb. Haemost. doi: 10.1111/jth.14846 contributor: fullname: Tripodi – year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0070 article-title: A diagnostic solution for haemostasis laboratories for patients taking direct oral anticoagulants using DOAC-Remove publication-title: Br. J. Haematol. doi: 10.1111/bjh.16091 contributor: fullname: Cox-Morton – volume: 39 start-page: 66 year: 2017 ident: 10.1016/j.thromres.2021.06.001_bb0080 article-title: Development of an UHPLC-UV-method for quantification of direct Oral anticoagulants: apixaban, rivaroxaban, dabigatran, and its prodrug dabigatran etexilate in human serum publication-title: Ther. Drug Monit. doi: 10.1097/FTD.0000000000000355 contributor: fullname: Boehr – volume: 41 start-page: 227 year: 2019 ident: 10.1016/j.thromres.2021.06.001_bb0065 article-title: Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban publication-title: Int. J. Lab. Hematol. doi: 10.1111/ijlh.12950 contributor: fullname: Platton – volume: 163 start-page: 117 year: 2018 ident: 10.1016/j.thromres.2021.06.001_bb0030 article-title: Simple method for removing DOACs from plasma samples publication-title: Thromb. Res. doi: 10.1016/j.thromres.2018.01.047 contributor: fullname: Exner – volume: 88 start-page: 583 year: 2002 ident: 10.1016/j.thromres.2021.06.001_bb0110 article-title: Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA publication-title: Thromb. Haemost. doi: 10.1055/s-0037-1613259 contributor: fullname: Tripodi |
SSID | ssj0017195 |
Score | 2.4425786 |
Snippet | Lupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral... BACKGROUNDLupus anticoagulant (LA)-detection in anticoagulated patients is an unmet need, which becomes even more cogent with the introduction of direct oral... |
SourceID | proquest crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 32 |
SubjectTerms | Dilute Russel viper venom Direct oral anticoagulants Silica clotting time |
Title | Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection |
URI | https://dx.doi.org/10.1016/j.thromres.2021.06.001 https://search.proquest.com/docview/2541321419 |
Volume | 204 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB5qBfEiPvHNCl7TbpJNsnuUolTFnip4CzubBCo1KZooXvztzuZRVBAPHhMyYTM7mW-GmW8H4FyisRRHzxEG0RHoc3vkrXAMZkiAnlmbsd0Wk3B8L24egocejDoujG2rbH1_49Nrb93eGbbaHC5mM8vxFcqXQlLSwv1A-iuwSnAkRB9WL65vx5NlMSFyVTPIQCjHCnwhCj8O7DSCJ8psKVX03EFTmvgNo3546xqCrjZho40d2UWzvC3opfk2rN211fEdWFzXlEdWZEwz-qAnO01Jz-fvTL_q2dySpBjlgiOm8aV4RoIbVuSsfCvY8tCIhNWIllS0VkbxLJtXi-qFkfrJYrQdW09CSVrWDVz5LkyvLqejsdNOVHCML4LSCSKeKAqANJeU6WRKZiLMUHsRz2w1xs8kCt8Y5GnkIdchp9ibXEKkeBIihYJ70M-LPN0HxhPa4kgHMgyl0IlBN1GoDNeR0CY1eADDToXxojk3I-4ayh7jTumxVXrcdNYdgOo0HX-zgJic-5-yZ93WxPR72JqHztOioocCQmnPFa46_Mf7j2DdXjWNf8fQL5-r9ISCkRJPYWXw4Z62JvcJRKTghw |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9swDBbSDlh3KbpH0fc0oFcnsi3b0rEIWqRd2lMG9CaIsg2kSOwgsTfs0t9e0o9iHVD00KstGTIpkR_BjyJj5woclTgGnnQAnoRQ0JW30nOQAzr0nPYMsS3u4skveXMf3Q_YuK-FIVplZ_tbm95Y6-7JqJPmaDWfU42v1KGSCoMWEUYq3GIfCA0Qr2v4-Mzz8BNft20MpPZo-D9lwg9D6kWwxLgWA8XAH7aJidc81H-2unFAV3tst0OO_KJd3Gc2yIov7ONtlxv_ylbXTcEjL3NuOf7Oknop2cXiL7e_7XxBJVIcI8Ext7Ap14DOhpcFr_6U_PnKiJQ3_iytca0c0Sxf1Kt6w1H4uF8sNa3HSWlWNfSt4hubXV3OxhOv66fguVBGlRclItUIf6xQGOfkWuUyzsEGicgpFxPmCmToHIgsCUDYWCDyRoOQaJHGgEBwn20XZZEdMC5SVHBiIxXHStrUgZ9q0E7YRFqXOThko16EZtXemmF6OtmD6YVuSOim5dUdMt1L2rzQv0HT_ubcH71qDB4OynjYIitrHBShjw586eujd3z_O9uZzG6nZnp99_OYfaI3LQXwhG1X6zo7RVhSwVmz7Z4ARV3hXA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+a+commercially+available+DOAC+absorbent+on+two+integrated+procedures+for+lupus+anticoagulant+detection&rft.jtitle=Thrombosis+research&rft.au=Tripodi%2C+Armando&rft.au=Scalambrino%2C+Erica&rft.au=Chantarangkul%2C+Veena&rft.au=Paoletti%2C+Oriana&rft.date=2021-08-01&rft.issn=0049-3848&rft.volume=204&rft.spage=32&rft.epage=39&rft_id=info:doi/10.1016%2Fj.thromres.2021.06.001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_thromres_2021_06_001 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0049-3848&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0049-3848&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0049-3848&client=summon |